IFCI Limited is a Government-owned NBFC whose lending book is shut, making its quarterly print a story of asset resolution, treasury marks and scheme-advisory fees rather than loan growth. The Q2 FY 2026-2027 print will speak to two things above all: whether the negative capital position (CRAR at (17.58)% vs the 15% RBI minimum) draws any restoration or merger-linked commentary, and how the fair-value and finance-cost lines move after a quarter in which G-sec yields hardened.
| Results date | November 12, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 125.40 Cr (standalone total income, Q1 FY27) |
| Previous quarter PAT | Rs. 8.64 Cr (standalone, Q1 FY27) |
| Market cap | Rs. 16,518.84 Cr |
| CMP | Rs. 61.31 |
Per the exchange intimation, the Board meeting is scheduled for Nov 12, 2026 to consider the Q2/H1 FY27 unaudited financial results, with the trading window closed till Nov 14, 2026.
No dividend has been declared on the Equity Shares for FY 2025-26, as the company reported insufficient profits. The FY27 dividend stance is one of the items to watch with the upcoming results.
The Q2 FY27 print will test whether IFCI's standalone P&L, dependent on impairment reversals and treasury marks, can hold up in a rising-yield quarter.
The 10-year G-sec yield rose roughly 40-45 bps over the quarter — from 6.79% on Aug 7 to 7.19% by Sep 28 after the RBI announced Rs. 1 lakh crore of OMO sales — making the fair-value line the biggest swing factor after Q1's net loss of Rs. (28.13) Cr on fair value changes, against a finance cost of Rs. 103.61 Cr on total income of just Rs. 125.40 Cr.
On the fee side, the PLI-Auto acceleration is a direct tailwind: Rs. 1,717.24 Cr of incentive claims were disbursed in August 2026 alone through IFCI as Central Nodal Agency, with the Heavy Industries Ministry expecting FY27 auto-PLI disbursal of about Rs. 4,700 Cr, more than double the roughly Rs. 2,322 Cr paid in the first two years.
The negative-CRAR overhang enters the quarter unresolved — (17.58)% at Jun 30, 2026 against the 15% RBI minimum — with ICRA noting the GoI infused nothing in FY2026 and has not earmarked any infusion for FY2027, while GoI approval for the IFCI Group consolidation with Stock Holding Corporation of India Ltd and IFCI Factors Ltd remains pending with no timeline.
The two dated commitments to test are the Rs. 9.20 Cr net-positive CAG corrective action committed for Q1 FY27 but not confirmed in the Q1 filing, and the IIDL Suites disposal that was due for completion by June 2026.
CRAR trajectory vs the 15% RBI minimum: Capital adequacy is the central overhang on the print.
CAG corrective action and recovery run-rate
IFCI Group consolidation and IIDL Suites disposal
Fair-value and finance-cost lines: The two biggest earnings swing items for the quarter.
Governance, dividend stance and investor engagement
The Department of Financial Services and IFCI's Board accorded in-principle approval in November 2024 for merger/amalgamation of group companies including Stock Holding Corporation of India Ltd and IFCI Factors Ltd, but the matter remains under process. As of the September 2026 rating notes, GoI approval was still pending and no scheme of arrangement had been approved by any competent authority during FY26.
Management committed to corrective action in Q1 FY27 with a net positive impact of Rs. 9.20 crore on the Profit and Loss Account, following CAG observations on Security Receipts and a misapplied PD on a Shriram EPC loan. The Q1 FY27 results announcement did not confirm whether this was booked, making it a follow-up point for the Q2 call.
Gross NPAs declined Rs. 68.16 Cr (-1.90%) during the June 2026 quarter to Rs. 3,521.81 Cr (95.68%), from Rs. 3,589.97 Cr (95.79%) at Mar 31, 2026, with the net credit-impaired ratio easing to 78.20%. Asset quality remains the central issue, with Corporate Borrowers at 95.79% of total advances and a Provision Coverage Ratio of 73.16%.
Disclaimer: This earnings preview is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.